News

Home/News
News 2017-06-21T13:15:59+00:00
November 7, 2017
VALNEVA Signs $39.6 Million IXIARO® Supply Contract with US Government
Lyon (France), November 7, 2017 - Valneva SE ("Valneva" or "the Company"),  a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines, ...
November 6, 2017
VALNEVA to Present at Jefferies and Stifel 2017 Healthcare Conferences
Lyon (France), November 06, 2017 - Valneva SE ("Valneva" or "the Company"), a leading commercial stage biotech company focused on developing innovative lifesaving vaccines, today ...
November 6, 2017
TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced a regulatory update regarding the New Drug Application (NDA) for TX-004HR, the ...
November 6, 2017
TherapeuticsMD Announces Third Quarter 2017 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced its financial results for the quarter ended September 30, 2017. ...
November 6, 2017
VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan
TEL AVIV, Israel, Nov. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
November 6, 2017
Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates
WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
November 6, 2017
Reata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week Meeting
IRVING, Texas, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today provided an update on the ...
November 6, 2017
Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences
PALO ALTO, Calif., Nov. 6, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today ...
November 6, 2017
Achaogen to Present at the Stifel 2017 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
November 6, 2017
Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress
SAN DIEGO, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of ...
November 6, 2017
UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder
RA’ANANA, Israel and NEW YORK, Nov. 06, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs ...
November 6, 2017
Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ...
November 6, 2017
Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
ROCKVILLE, Md., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative therapeutics for the treatment of ...
November 2, 2017
For the First Time Ever, There Will be a Full Week Dedicated to Plasminogen Deficiency (PLGD) !
LAVAL, QC, Nov. 2, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF), ("Prometic") is pleased to invite you to participate in a full week of ...
November 2, 2017
Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting
AUSTIN, Texas, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...
November 2, 2017
Basilea reports on commercial progress of antifungal Cresemba® in Europe
Basel, Switzerland, November 2, 2017 - Basilea Pharmaceutica Ltd. (BSLN.SW) announced today that its licensing partner Pfizer recently launched the antifungal drug Cresemba® (isavuconazole) in ...
November 2, 2017
Zealand reports royalty revenue for the third quarter of 2017
Copenhagen, November 2, 2017 - Zealand Pharma ("Zealand") reports Q3 2017 royalty revenue from Sanofi's sales of Lyxumia®/Adlyxin® (lixisenatide) of DKK 5.0 million/USD 0.8 million ...
November 2, 2017
AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease
Lausanne, Switzerland, November 2, 2017 - AC Immune SA (ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today ...
November 2, 2017
Aradigm Announces Third Quarter 2017 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (ARDM) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2017. ...
November 2, 2017
Bioblast Pharma Reports Third Quarter 2017 Financial Results
TEL AVIV, Israel, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the ...
Page 11 of 48